98 related articles for article (PubMed ID: 24324104)
1. Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.
Yokomise H; Liu D; Ishikawa S; Go T; Gotoh M; Okuda M; Tarumi S; Kasai Y; Matsuura N
Anticancer Res; 2013 Dec; 33(12):5597-602. PubMed ID: 24324104
[TBL] [Abstract][Full Text] [Related]
2. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
3. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.
Jakobsen JN; Santoni-Rugiu E; Ravn J; Sørensen JB
Eur J Cancer; 2013 Jul; 49(11):2494-503. PubMed ID: 23639410
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
[TBL] [Abstract][Full Text] [Related]
5. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
[TBL] [Abstract][Full Text] [Related]
6. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
8. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
10. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
11. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer.
Fischer JR; Manegold C; Bülzebruck H; Vogt-Moykopf I; Drings P
Semin Oncol; 1994 Jun; 21(3 Suppl 4):20-7. PubMed ID: 7516094
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery.
Yokomise H; Liu D; Chang S; Go T; Ishikawa S; Misaki N; Nakashima N
Anticancer Res; 2013 Mar; 33(3):1107-15. PubMed ID: 23482788
[TBL] [Abstract][Full Text] [Related]
15. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.
De Pas T; Pelosi G; de Braud F; Veronesi G; Curigliano G; Leon ME; Danesi R; Noberasco C; d'Aiuto M; Catalano G; Viale G; Spaggiari L
J Clin Oncol; 2004 Dec; 22(24):4966-70. PubMed ID: 15611511
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
[TBL] [Abstract][Full Text] [Related]
17. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
18. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
[TBL] [Abstract][Full Text] [Related]
19. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
Wirth LJ; Lucca J; Ostler P; Fidias P; Lynch C; Jänne PA; Herbst RS; Johnson BE; Sugarbaker DJ; Mathisen DJ; Lukanich JM; Choi NC; Berman SM; Skarin AT
Clin Cancer Res; 2003 May; 9(5):1698-704. PubMed ID: 12738723
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]